Clinical Trials | December 04, 2025
Eli Lilly pledges $40 million to Indiana University to expand clinical trials
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
The deal aims to address long-standing imbalances in pharmaceutical trade while boosting investment and innovation on both sides of the Atlantic
Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
New site expands manufacturing footprint to meet future demand; ensures continued on-time delivery rate of >99.9% to patients across western US, Alaska and Hawaii
This latest commitment brings the British pharmaceutical company’s total investment at the site to $886 million
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
Netherlands site will bring 500 manufacturing and 1,500 construction jobs while further strengthening Lilly's global supply chain
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
Subscribe To Our Newsletter & Stay Updated
